Benchmark Reiterates View on Bio-Reference Labs

Benchmark has published a research report on Bio-Reference Labs BRLI. In the report, Benchmark wrote, "Revenue in F3Q11 expanded 21.6% to $148.0 million, which exceeded the $146.3 million consensus and nearly met our $148.5 million forecast. Pro-forma EPS expanded 25.6% to $0.36, which exceeded our consensus-matching $0.34 forecast." Benchmark rated Bio-Reference Labs a BUY with a price target of $29.00. Bio-Reference Labs closed Thursday at $18.92.